source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitalsSeveral of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…